Marcos Rogerio de Lima has been suspended one year by UFC anti-doping for a failed drug test – his second career violation.
Thursday, UFC drug testing program Combat Sports Anti-Doping (CSAD) announced the violation and punishment, which renders de Lima (22-9-1 MMA, 11-7 UFC) unable to compete until Jan. 24, 2026.
According to CSAD, de Lima tested positive in an out-of-competition urinalysis for anastrozole, which it defines as a hormone and metabolic modulator that is prohibited at all times by the UFC.
CSAD traced the positive test back to a medication de Lima was taking for a documented medical condition. However, the medication stated anastrozole on the label, which de Lima did not check. He did not apply for a therapeutic use exemption (TUE).
Due to the circumstances of the positive test and de Lima’s cooperation, a six-month suspension was determined appropriate for the individual violation. However, the secondary nature of the drug-testing violation increased CSAD’s suspension to one year. De Lima’s first drug test failure was in 2017 and stemmed from a contaminated supplement.
De Lima, 39, most recently competed in February when he defeated Junior Tafa to win his third fight in four outings. He was scheduled to fight Kennedy Nzechukwu in October but withdrew from the bout.
